Story

Legend Biotech Stock Jumps on Strong CARVYKTI Sales and Q2 Earnings Beat

ENTHMSVIIDZHZH-TWJAKOHI
Aug 11, 20262 min read
Legend Biotech Stock Jumps on Strong CARVYKTI Sales and Q2 Earnings Beat
Text size
Background

Legend Biotech (NASDAQ: LEGN) shares rose sharply in pre-market trading after the company announced second-quarter 2026 financial results that significantly exceeded analyst forecasts, driven by robust sales of its flagship cell therapy, CARVYKTI. The company posted a decisive swing to profitability, boosting investor confidence in its commercial execution and pipeline.

Earnings Exceed Expectations

Legend Biotech reported total revenue of $387.5 million for the quarter ended June 30, 2026, a substantial increase from $255.1 million in the same period a year earlier. The strong top-line performance translated directly to the bottom line, resulting in a notable turnaround.

Key financial highlights from the release include:

  • Net Income: $33.2 million, compared to a net loss of $125.4 million in the prior-year quarter.
  • Adjusted EPS: $0.16, more than double the consensus analyst estimate of $0.07.
  • Operating Income: $57.7 million, reversing an operating loss from the year before.

The primary growth driver was CARVYKTI, a CAR-T therapy for multiple myeloma. The company reported that net trade sales for the treatment grew 50% year-over-year to approximately $657 million, supported by its expanding global presence across 348 sites in 19 markets.

Market Reaction and Strategic Context

Sample IUX Markets – In-articleAd

Investors reacted positively to the news, sending the stock up 6.5% in pre-open trading. The results helped address a key question for investors regarding whether CARVYKTI's growth could maintain its lead over rival treatments, particularly Johnson & Johnson's Tecvayli. This strong commercial performance appears to have affirmed the therapy's growth trajectory.

"Commercial momentum of CARVYKTI provides the foundation to advance a diversified portfolio of next-generation cell therapies," said Interim CEO Alan Bash in the earnings announcement, highlighting the company's strategy to leverage current success to fund future innovation.

Pipeline and Financial Health

Beyond the strong commercial results, Legend Biotech also provided positive updates on its pipeline, including first-in-human data for its in vivo CAR-T candidate LB2501 and its DLL3-targeted program LB2102. These developments add to the company's long-term growth narrative.

The company ended the quarter with a solid financial position, holding approximately $965 million in cash, cash equivalents, and time deposits. This provides a strong footing as it continues to scale its operations and advance its clinical programs.

Read next

More on Stocks
Back to latest news

LATEST